Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;25(1):2366451.
doi: 10.1080/15384047.2024.2366451. Epub 2024 Jun 10.

Role of transforming growth factor-β1 pathway in angiogenesis induced by chronic stress in colorectal cancer

Jie Zhang  1 , Yao-Tiao Deng  2 , Jie Liu  2 , Lu Gan  1 , Yu Jiang  2
Affiliations

Role of transforming growth factor-β1 pathway in angiogenesis induced by chronic stress in colorectal cancer

Jie Zhang et al. Cancer Biol Ther. .

Abstract

Background: Chronic stress can induce stress-related hormones; norepinephrine (NE) is considered to have the highest potential in cancer. NE can stimulate the expression of hypoxia-inducible factor-1α (HIF-1α), which is associated with vascular endothelial growth factor (VEGF) secretion and tumor angiogenesis. However, the underlying mechanisms are poorly understood.

Methods: Tumor-bearing mice were subjected to chronic restraint stress and treated with normal saline, human monoclonal VEGF-A neutralizing antibody bevacizumab, or β-adrenergic receptor (β-AR) antagonist (propranolol). Tumor growth and vessel density were also evaluated. Human colorectal adenocarcinoma cells were treated with NE, propranolol, or the inhibitor of transforming growth factor-β (TGF-β) receptor Type I kinase (Ly2157299) in vitro. TGF-β1 in mouse serum and cell culture supernatants was quantified using ELISA. The expression of HIF-1α was measured using Real time-PCR and western blotting. Cell migration and invasion were tested.

Results: Chronic restraint stress attenuated the efficacy of bevacizumab and promoted tumor growth and angiogenesis in a colorectal tumor model. Propranolol blocked this effect and inhibited TGF-β1 elevation caused by chronic restraint stress or NE. NE upregulated HIF-1α expression, which was reversed by propranolol or Ly2157299. Propranolol and Ly2157199 blocked NE-stimulated cancer cell migration and invasion.

Conclusions: Our results demonstrate the effect of NE on tumor angiogenesis and the critical role of TGF-β1 signaling during this process. In addition, β-AR/TGF-β1 signaling/HIF-1α/VEGF is a potential signaling pathway. This study also indicates that psychosocial stress might be a risk factor which weakens the efficacy of anti-angiogenic therapy.

Keywords: Chronic stress; angiogenesis; hypoxia inducible factor-1α; norepinephrine; transforming growth factor-β1.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Chronic restraint stress promoted tumor growth and weakened the efficacy of bevacizumab.
Figure 2.
Figure 2.
Propranolol inhibited chronic restraint stress-stimulated angiogenesis in vivo.
Figure 3.
Figure 3.
Chronic restraint stress and norepinephrine induced TGF-β1 secretion.
Figure 4.
Figure 4.
The mRNA and protein expression of TGF-βRI in HT-29 and SW480 cells after norepinephrine treatment.
Figure 5.
Figure 5.
Propranolol or Ly2157299 blocked norepinephrine-induced mRNA and protein expression of HIF-1α.
Figure 6.
Figure 6.
Norepinephrine stimulated HT-29 and SW480 cells migration and invasion.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Carmeliet P, Jain RK.. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–12. doi:10.1038/nature10144. - DOI - PMC - PubMed
    1. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31(9):1219–30. doi:10.1200/JCO.2012.46.2762. - DOI - PubMed
    1. Recondo G Jr., Diaz-Canton E, de la Vega M, Greco M, Recondo G Sr., Valsecchi ME. Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol. 2014;6(7):211–24. doi:10.4251/wjgo.v6.i7.211. - DOI - PMC - PubMed
    1. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin(r)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi:10.1016/j.ctrv.2020.102017. - DOI - PubMed
    1. Chen N, Ren M, Li R, Deng X, Li Y, Yan K, Xiao L, Yang Y, Wang L, Luo M. et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma. Mol Cancer. 2015;14(1):140. doi:10.1186/s12943-015-0418-x. - DOI - PMC - PubMed

MeSH terms